MARKET

GBT

GBT

Global Blood
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.52
+0.38
+1.45%
Pre Market: 25.55 -0.97 -3.66% 06:13 09/24 EDT
OPEN
26.30
PREV CLOSE
26.14
HIGH
26.77
LOW
25.99
VOLUME
6
TURNOVER
--
52 WEEK HIGH
64.49
52 WEEK LOW
25.48
MARKET CAP
1.66B
P/E (TTM)
-6.1743
1D
5D
1M
3M
1Y
5Y
Yiheng Capital Management, L.P. Buys ACM Research Inc, TAL Education Group, Generation Bio Co, ...
GuruFocus News · 2d ago
GBT Announces Participation at the Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Cantor Global Healthcare Conference on Monday, September 27, 2021...
GlobeNewswire · 4d ago
Sickle Cell Disease Drugs Market: Industry Outlook, Classification, Demand, Regional Analysis and Forecast to 2030
Research Nester released a report titled which delivers a detailed overview of the global sickle cell disease drugs market in terms of market segmentation by treatment type, disease type, end-user, and by region.
AmericaNewsHour · 09/16 06:17
GBT Establishes The GBT Foundation to Improve the Health and Well-being of Underserved Patient Communities Around the World
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced the launch of The GBT Foundation, a 501(c)(3) organization and source of charitable giving that will work to improve the health an...
GlobeNewswire · 09/14 15:00
Director Of Global Blood Therapeutics Makes $145.00 Thousand Sale
Scott Morrison, Director at Global Blood Therapeutics (NASDAQ:GBT), made a large insider sell on September 9, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Morrison so...
Benzinga · 09/13 16:45
A Trio of Stocks Growing Capex Fast
GuruFocus News · 09/09 15:53
GBT Announces New Employment Inducement Grants
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on September 1, 2021, the compensation committee of GBT's board of directors granted 20 new employees options to purchase an aggregate of 49,600 shares of the company's common stock w...
GlobeNewswire · 09/09 12:00
GBT and Sickle Cell Disease Association of America to Host 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 10 Annual Sickle Cell Disease (SCD) Therapeutics Conference on Wednesday, September 15th. The virtual conference, which takes...
GlobeNewswire · 09/08 21:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GBT. Analyze the recent business situations of Global Blood through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GBT stock price target is 72.47 with a high estimate of 138.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 325
Institutional Holdings: 69.15M
% Owned: 110.80%
Shares Outstanding: 62.41M
TypeInstitutionsShares
Increased
80
6.87M
New
21
986.56K
Decreased
54
5.99M
Sold Out
41
3.01M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
President/Chief Executive Officer/Director
Ted Love
Chief Financial Officer
Jeffrey Farrow
Chief Human Resource Officer
Eric Fink
Chief Scientific Officer
Brian Cathers
Other
Jung Choi
Other
David Johnson
Other
Tricia Suvari
Lead Director/Independent Director
Mark Perry
Independent Director
Willie Brown
Independent Director
Scott Morrison
Independent Director
Deval Patrick
Independent Director
Glenn Pierce
Independent Director
Philip Pizzo
Independent Director
Dawn Svoronos
Independent Director
Alexis Thompson
Independent Director
Wendy Yarno
No Data
About GBT
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Webull offers kinds of Global Blood Therapeutics Inc stock information, including NASDAQ:GBT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GBT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GBT stock methods without spending real money on the virtual paper trading platform.